VIRTUAL: Thyroid Eye Disease and the use of Teprotumumab featuring Behin Barahimi, MD
2.5 Hour(s) of CME
5:00 pm - 6:30 pm Case Presentations
6:30 pm - 7:30 pm Keynote Lecture
what is the mechanism of action of teprotumumab
when should teprotumumab be prescribed for thyroid eye disease
what are the adverse affects of the medication that we need to be aware of
This meeting is being co-sponsored by the University of Minnesota.
Dr. Behin Barahimi is an oculoplastic, orbital and reconstructive surgeon. She is a native of Nashville and received her M.D. from Vanderbilt School of Medicine. Dr Barahimi completed her ophthalmology training at the Wills Eye Institute in Philadelphia where she also served as chief resident. She was then selected by the University of Minnesota to complete an American Society of Ophthalmic and Plastic Surgery sponsored fellowship. In 2013, she elected to return to her home- town and join the faculty at the Vanderbilt Eye Institute.